NZ334268A - Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride - Google Patents
Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochlorideInfo
- Publication number
- NZ334268A NZ334268A NZ334268A NZ33426897A NZ334268A NZ 334268 A NZ334268 A NZ 334268A NZ 334268 A NZ334268 A NZ 334268A NZ 33426897 A NZ33426897 A NZ 33426897A NZ 334268 A NZ334268 A NZ 334268A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alpha
- methoxyimino
- azabicyclo
- oct
- dosage form
- Prior art date
Links
- PWUBONDMIMDOQY-UHFFFAOYSA-N acetonitrile;hydrochloride Chemical compound Cl.CC#N PWUBONDMIMDOQY-UHFFFAOYSA-N 0.000 title abstract 2
- 238000013270 controlled release Methods 0.000 title abstract 2
- 239000002552 dosage form Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 abstract 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 abstract 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical group CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9619074.9A GB9619074D0 (en) | 1996-09-12 | 1996-09-12 | Composition |
| PCT/GB1997/002418 WO1998010762A2 (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of r-(z)-alpha-methoxyimino-alpha-(1-azabicyclo2.2oct-c-yl)acetonitrile monohydrochloride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ334268A true NZ334268A (en) | 2000-10-27 |
Family
ID=10799833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ334268A NZ334268A (en) | 1996-09-12 | 1997-09-08 | Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0929301A2 (https=) |
| JP (1) | JP2001500150A (https=) |
| KR (1) | KR20000036039A (https=) |
| CN (2) | CN1235544A (https=) |
| AR (1) | AR008176A1 (https=) |
| AU (1) | AU724086B2 (https=) |
| BR (1) | BR9711734A (https=) |
| CA (1) | CA2265661A1 (https=) |
| CO (1) | CO5031291A1 (https=) |
| CZ (1) | CZ83299A3 (https=) |
| GB (1) | GB9619074D0 (https=) |
| HU (1) | HUP9904401A3 (https=) |
| ID (1) | ID19589A (https=) |
| IL (1) | IL128781A0 (https=) |
| MA (1) | MA24359A1 (https=) |
| NO (1) | NO991194D0 (https=) |
| NZ (1) | NZ334268A (https=) |
| PE (1) | PE2499A1 (https=) |
| PL (1) | PL332074A1 (https=) |
| TR (1) | TR199900505T2 (https=) |
| WO (1) | WO1998010762A2 (https=) |
| ZA (1) | ZA978133B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2775597B1 (fr) * | 1998-03-04 | 2001-04-20 | Gattefosse Ets Sa | Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication |
| JP2002506031A (ja) | 1998-03-11 | 2002-02-26 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 組成物 |
| DE19918325A1 (de) * | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
| FR2796840B1 (fr) | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | Comprimes faiblement doses et procede de preparation |
| US6733781B2 (en) * | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
| PA8578501A1 (es) | 2002-07-25 | 2005-02-04 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
| JP4808612B2 (ja) | 2003-04-25 | 2011-11-02 | 田辺三菱製薬株式会社 | アルキレンジオキシベンゼン誘導体を含む経口投与用組成物 |
| ATE339192T1 (de) * | 2003-05-14 | 2006-10-15 | Eurand Pharmaceuticals Ltd | Kontrollierte medikamentfreigabe zusammensetzung mit in vivo mechanikstresswiderstand |
| US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| JP2005272347A (ja) * | 2004-03-24 | 2005-10-06 | Ohara Yakuhin Kogyo Kk | 固形製剤の製造方法 |
| CN101022788B (zh) | 2004-08-13 | 2010-11-10 | 贝林格尔·英格海姆国际有限公司 | 包含普拉克索或其可药用盐的延长释放小球制剂、其制备方法及其用途 |
| UA93608C2 (ru) | 2004-08-13 | 2011-02-25 | Берингер Ингельхайм Интернациональ Гмбх | композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ |
| EP1970056A1 (en) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Time-specific delayed/pulsatile release dosage forms |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| WO2020214879A1 (en) * | 2019-04-19 | 2020-10-22 | Steven Hoffman | Sustained release formulations |
| WO2026013570A1 (en) | 2024-07-09 | 2026-01-15 | Syremis Therapeutics Ltd. | New salt forms of sabcomeline |
| WO2026013566A1 (en) | 2024-07-09 | 2026-01-15 | Syremis Therapeutics Ltd. | New salt forms of sabcomeline |
| WO2026013573A1 (en) | 2024-07-09 | 2026-01-15 | Syremis Therapeutics Ltd. | New salt forms of sabcomeline |
| WO2026013563A1 (en) | 2024-07-09 | 2026-01-15 | Syremis Therapeutics Ltd. | New salt forms of sabcomeline |
| WO2026018154A1 (en) | 2024-07-16 | 2026-01-22 | Syremis Therapeutics Ltd. | Combinations of sabcomeline with non-cns penetrant muscarinic antagonists |
| WO2026018155A1 (en) | 2024-07-16 | 2026-01-22 | Syremis Therapeutics Ltd. | Combinations of sabcomeline with long-acting non-cns penetrant muscarinic antagonists |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG48315A1 (en) * | 1989-04-13 | 1998-04-17 | Beecham Group Plc | Novel compounds |
| GB9409718D0 (en) * | 1994-05-14 | 1994-07-06 | Smithkline Beecham Plc | Novel compounds |
| GB9421472D0 (en) * | 1994-10-25 | 1994-12-07 | Smithkline Beecham Plc | Novel methods |
| AR004178A1 (es) * | 1995-07-29 | 1998-11-04 | Smithkline Beecham Plc | Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma. |
-
1996
- 1996-09-12 GB GBGB9619074.9A patent/GB9619074D0/en active Pending
-
1997
- 1997-09-08 JP JP10513352A patent/JP2001500150A/ja active Pending
- 1997-09-08 NZ NZ334268A patent/NZ334268A/xx unknown
- 1997-09-08 EP EP97939064A patent/EP0929301A2/en not_active Withdrawn
- 1997-09-08 TR TR1999/00505T patent/TR199900505T2/xx unknown
- 1997-09-08 CN CN97199411A patent/CN1235544A/zh active Pending
- 1997-09-08 KR KR1019997002030A patent/KR20000036039A/ko not_active Ceased
- 1997-09-08 CA CA002265661A patent/CA2265661A1/en not_active Abandoned
- 1997-09-08 IL IL12878197A patent/IL128781A0/xx unknown
- 1997-09-08 AU AU41288/97A patent/AU724086B2/en not_active Ceased
- 1997-09-08 HU HU9904401A patent/HUP9904401A3/hu unknown
- 1997-09-08 BR BR9711734A patent/BR9711734A/pt unknown
- 1997-09-08 CZ CZ99832A patent/CZ83299A3/cs unknown
- 1997-09-08 PL PL97332074A patent/PL332074A1/xx unknown
- 1997-09-08 WO PCT/GB1997/002418 patent/WO1998010762A2/en not_active Ceased
- 1997-09-09 CO CO97052280A patent/CO5031291A1/es unknown
- 1997-09-10 ZA ZA978133A patent/ZA978133B/xx unknown
- 1997-09-10 ID IDP973137A patent/ID19589A/id unknown
- 1997-09-10 PE PE1997000805A patent/PE2499A1/es not_active Application Discontinuation
- 1997-09-10 MA MA24792A patent/MA24359A1/fr unknown
- 1997-09-10 AR ARP970104130A patent/AR008176A1/es not_active Application Discontinuation
-
1999
- 1999-03-11 NO NO991194A patent/NO991194D0/no unknown
-
2003
- 2003-01-23 CN CN03102977A patent/CN1446535A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR008176A1 (es) | 1999-12-09 |
| NO991194L (no) | 1999-03-11 |
| WO1998010762A2 (en) | 1998-03-19 |
| AU724086B2 (en) | 2000-09-14 |
| EP0929301A2 (en) | 1999-07-21 |
| JP2001500150A (ja) | 2001-01-09 |
| CO5031291A1 (es) | 2001-04-27 |
| CN1446535A (zh) | 2003-10-08 |
| PE2499A1 (es) | 1999-03-24 |
| ID19589A (id) | 1998-07-23 |
| WO1998010762A3 (en) | 1998-06-04 |
| PL332074A1 (en) | 1999-08-30 |
| AU4128897A (en) | 1998-04-02 |
| NO991194D0 (no) | 1999-03-11 |
| ZA978133B (en) | 1999-04-12 |
| CN1235544A (zh) | 1999-11-17 |
| CZ83299A3 (cs) | 1999-08-11 |
| GB9619074D0 (en) | 1996-10-23 |
| HUP9904401A3 (en) | 2001-03-28 |
| HUP9904401A2 (hu) | 2000-06-28 |
| IL128781A0 (en) | 2000-01-31 |
| MA24359A1 (fr) | 1998-07-01 |
| TR199900505T2 (https=) | 1999-06-21 |
| CA2265661A1 (en) | 1998-03-19 |
| KR20000036039A (ko) | 2000-06-26 |
| BR9711734A (pt) | 1999-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ334268A (en) | Controlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo [2.2.2]oct-3-yl) acetonitrile monohydrochloride | |
| GB2206788B (en) | 5 ht-3 antagonist for the treatment or reduction of dependence | |
| FI935306A7 (fi) | Puhdistettujen, pintaa modifioivien aineiden käyttö estämään hiukkasten kasautumista steriloinnin aikana | |
| IL114335A0 (en) | Pharmacologically active CNS compounds | |
| AU629777B2 (en) | Blocking agents of edrf effect or formation for the treatment of shock | |
| EG19511A (en) | Formation of high active detergent particles | |
| HUP0101043A3 (en) | Controlled release oral dosage form containing [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl]acetonitrile monohydrochlorid and process for its preparation | |
| TW414158U (en) | Construction of structural body | |
| NZ232946A (en) | Preparation of crystalline 17alpha-hydroxy-7alpha methyl-19-nor-17-pregn-5 | |
| AU1916192A (en) | Use of sigma receptor antagonists to enhance the effects of antipsychotic drugs | |
| ZA886247B (en) | Use of a compound for the treatment of schizophrenia | |
| HU896122D0 (en) | Process for the formation of active agents for waxed tablets | |
| IL89082A0 (en) | Compounds with a psychotropic action,agents containing them,and the use thereof for the treatment and prophylaxis of disorders of the central nervous system | |
| TR199900141T2 (xx) | Bunama tedavisi ve/veya profilaksisi i�in form�lasyon. | |
| GB9815383D0 (en) | Novel method of treatment | |
| HK1021336A (en) | Controlled release dosage form of [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl)acetonitrile monohydrochloride | |
| GB8730191D0 (en) | Pharmacologically active compounds & use | |
| GB8730192D0 (en) | Pharmacologically active compounds & use | |
| EP0598375A3 (en) | 5-thia-1,4-diazabycyclo(4.2.0)octane-3,8-dioxo analogs of beta-lactam, processesfor the preparation thereof and the use thereof. | |
| HU901306D0 (en) | Sprinkler body for managing to pass artificital fetilizer out | |
| RO105585B1 (ro) | Compozitie medicamentoasa folosita in tratamentul ulcerului de gamba | |
| HU9300520D0 (en) | Game of chance named "where is the ball?" | |
| GB8908561D0 (en) | Pharmaceutically active cns compounds | |
| ZA899327B (en) | Pharmaceutically active cns compounds | |
| IE882569L (en) | Composition for treatment of schizophrenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) |